September 29, 2014: ACTION Awarded 3-year Contract and Increased Cooperative Agreement Funding from FDA

ACTTION was awarded increased funding for Year 4 of its 5-year cooperative agreement, and was also awarded a 3-year contract from the FDA to conduct analyses of patient-level data from analgesic clinical trials submitted to the FDA. These analyses will focus on statistical aspects of analgesic trials, such as the accommodation of missing data, as well as the development and validation of composite outcome measures of pain and physical functioning and pain and rescue analgesic use. The inspiration and impetus for ACTTION was provided by the FDA, and the ongoing support of the agency has been essential to ACTTION’s success and accomplishments.